Education
About Us
Working with TipRanks
Follow Us
Biomarin Pharmaceutical Inc. (DE:BM8)
NASDAQ:BM8
BM8 Stock Chart & Stats
€50.96
€0.58(0.92%)
At close: 4:00 PM EST
€50.96
€0.58(0.92%)
Day’s Range― - ―
52-Week Range€43.86 - €67.38
Previous CloseN/A
Volume0.00
Average Volume (3M)45.00
Market Cap
€9.99B
Enterprise Value€10.98B
Total Cash (Recent Filing)€1.56B
Total Debt (Recent Filing)€642.87M
Price to Earnings (P/E)32.7
Beta0.47
Next Earnings
Apr 29, 2026EPS Estimate
0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding192,323,360
10 Day Avg. Volume59
30 Day Avg. Volume45
Financial Highlights & Ratios
PEG Ratio-1.71
Price to Book (P/B)1.87
Price to Sales (P/S)3.54
P/FCF Ratio15.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€77.41Price Target Upside51.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)3.43
Revenue Forecast (FY)€3.10B
Bulls Say, Bears Say
Bulls Say
Long‑acting Pipeline AssetA long‑acting CNP analog advancing into pivotal testing that enables weekly dosing and higher exposure could deliver improved outcomes and materially strengthen the company's competitive position if superiority is shown.
Strategic Acquisition And DiversificationPlanned acquisition of Amicus is expected to add two differentiated commercial therapies for large markets, diversifying revenue sources and enhancing the company's long‑term growth profile.
Voxzogo Clinical ProfileVoxzogo's strong efficacy and safety data combined with a broad label that allows initiation at younger ages supports sustained patient adoption and a leading position in achondroplasia treatment.
Bears Say
Asset Withdrawal And Expense ImpactWithdrawal of a late‑stage gene therapy and the related write‑down increased selling and administrative expenses, weighing on near‑term profitability and cash available for strategic initiatives.
Emerging Dosing And Oral CompetitionApproval of once‑weekly injectable rivals and development of daily oral FGFR drugs create more convenient alternatives to a once‑daily injection, posing direct pressure on market share.
Geographic Regulatory ExposureHeavy dependence on regions outside the United States means adverse regulatory outcomes in Europe could significantly reduce international sales and overall revenue growth.
BioMarin Pharmaceutical News
BM8 FAQ
What was Biomarin Pharmaceutical Inc.’s price range in the past 12 months?
Biomarin Pharmaceutical Inc. lowest stock price was €43.86 and its highest was €67.38 in the past 12 months.
What is Biomarin Pharmaceutical Inc.’s market cap?
Biomarin Pharmaceutical Inc.’s market cap is €9.99B.
When is Biomarin Pharmaceutical Inc.’s upcoming earnings report date?
Biomarin Pharmaceutical Inc.’s upcoming earnings report date is Apr 29, 2026 which is in 54 days.
How were Biomarin Pharmaceutical Inc.’s earnings last quarter?
Biomarin Pharmaceutical Inc. released its earnings results on Feb 23, 2026. The company reported -€0.205 earnings per share for the quarter, missing the consensus estimate of €0.145 by -€0.35.
Is Biomarin Pharmaceutical Inc. overvalued?
According to Wall Street analysts Biomarin Pharmaceutical Inc.’s price is currently Undervalued.
Does Biomarin Pharmaceutical Inc. pay dividends?
Biomarin Pharmaceutical Inc. does not currently pay dividends.
What is Biomarin Pharmaceutical Inc.’s EPS estimate?
Biomarin Pharmaceutical Inc.’s EPS estimate is 0.63.
How many shares outstanding does Biomarin Pharmaceutical Inc. have?
Biomarin Pharmaceutical Inc. has 192,323,360 shares outstanding.
What happened to Biomarin Pharmaceutical Inc.’s price movement after its last earnings report?
Biomarin Pharmaceutical Inc. reported an EPS of -€0.205 in its last earnings report, missing expectations of €0.145. Following the earnings report the stock price went down -2.503%.
Which hedge fund is a major shareholder of Biomarin Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in DE:BM8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€77.41 (51.89% Upside)
€77.41 (51.89% Upside)
Blogger Sentiment
Bullish
DE:BM8 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 79%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.91%
12-Months-Change
Fundamentals
Return on Equity
5.94%
Trailing 12-Months
Asset Growth
8.66%
Trailing 12-Months
Company Description
Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BM8 Company Deck
BM8 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial and operational performance: record revenues, strong YOY growth for Voxzogo and enzyme therapies, improved profitability (non-GAAP EPS and operating cash flow), clear near-term R&D catalysts, and strategic acquisitions that should expand the portfolio and future revenues. Headwinds were acknowledged and quantified — notably the Roctavian withdrawal and related charges, one-time Q4 order timing effects leading to a weaker Q1, lower royalty expectations, routine market-access renegotiations in select countries, and modest near-term dilution and costs tied to the Amicus acquisition. Management provided concrete 2026 guidance (excluding Amicus post-close contributions) and explained assumptions for competitive scenarios. Overall, positives (robust growth, cash generation, pipeline catalysts, and strategic M&A) outweigh the defined near-term and one-time negatives.View all DE:BM8 earnings summariesBM8 Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BM8 Stock 12 Month Forecast
Average Price Target
€77.41
▲(51.89% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―
Options Prices
Currently, No data available
---